ArticleFrontiers in microbiology2025
Impact of COVID-19 therapeutics on the development of post-infectious lung fibrosis.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-COVID-19 pulmonary fibrosis (PCPF) is a significant long-term complication in survivors of COVID-19. In this study, we aimed to identify clinical risk factors for PCPF and evaluate the impact of COVID-19-related therapies. Methods: We retrospectively studied hospitalized adults with confirmed COVID-19 across three hospitals in South Korea from 2020 to 2022. Inclusion required chest computed tomography (CT) imaging both before and after COVID-19 infection. PCPF was defined as fibrotic changes seen on follow-up CT performed at least one month after recovery. Results: Among 5,720 hospitalized adults with COVID-19, 688 met the inclusion criteria, and 87 (12.6%) developed PCPF based on follow-up CT. In the multivariate logistic regression, pre-existing renal disease (adjusted odds ratio [aOR] 3.287; 95% confidential interval [CI]: 1.260-8.580; Conclusion: PCPF remains a relevant sequela in COVID-19 survivors. Remdesivir and baricitinib use were associated with a reduced and increased risk of PCPF, respectively. Although adjusted for multiple confounders, residual indication bias of each treatment cannot be completely excluded. Therefore, prospective studies are needed to validate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.